| Age in months, median (range) | 62 (2-190) |
| Female/male ratio | 71:95 |
| WBC × 109/L, median (range) | 24.1 (0.5-900) |
| BFM risk factor-150, median (range) | 1.05 (0.31-2.03) |
| FAB type | |
| L1 | 133 |
| L2 | 30 |
| AUL | 3 |
| Immunophenotype | |
| Pro-B | 6 |
| Common | 86 |
| Pre-B | 38 |
| T | 36 |
| DNA ploidy | |
| Nonhyperdiploid | 130 |
| Hyperdiploid | 20 |
| Unknown | 16 |
| Follow-up in months, median (range) | 46 (17-81) |
| Clinical response to PRD monotherapy | |
| Good | 144 |
| Poor | 12 |
| Unknown | 10 |
| Events | |
| No complete remission | 1 |
| Relapse | 43 |
| Early death | 2 |
| Toxic death | 3 |
| No event | 103 |
| Lost to follow-up or otherwise not evaluable | 14 |
| Age in months, median (range) | 62 (2-190) |
| Female/male ratio | 71:95 |
| WBC × 109/L, median (range) | 24.1 (0.5-900) |
| BFM risk factor-150, median (range) | 1.05 (0.31-2.03) |
| FAB type | |
| L1 | 133 |
| L2 | 30 |
| AUL | 3 |
| Immunophenotype | |
| Pro-B | 6 |
| Common | 86 |
| Pre-B | 38 |
| T | 36 |
| DNA ploidy | |
| Nonhyperdiploid | 130 |
| Hyperdiploid | 20 |
| Unknown | 16 |
| Follow-up in months, median (range) | 46 (17-81) |
| Clinical response to PRD monotherapy | |
| Good | 144 |
| Poor | 12 |
| Unknown | 10 |
| Events | |
| No complete remission | 1 |
| Relapse | 43 |
| Early death | 2 |
| Toxic death | 3 |
| No event | 103 |
| Lost to follow-up or otherwise not evaluable | 14 |
Abbreviation: AUL, acute undifferentiated leukemia.
A measure for the leukemic cell burden, based on peripheral leukemic cell count and liver and spleen size, as developed by the German Berlin-Frankfurt-Münster Group.10